SaadAdnanShakirMD

Neuropsychiatry

Dr. Saad A. Shakir, MD is a Neuro-psychiatrist in the San Francisco Bay Area. He is board-certified by the American Board of Psychiatry and Neurology, and also a distinguished fellow of the American psychiatric Association, and also a fellow of the An American College of international physicians. Presently he is practicing at Savant Care in Los Altos, CA.

Join to view full profile

Dr. Shakir is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Shakir's full profile

Already have an account?

Office
4966 El Camino Real
Suite 224
Los Altos, CA 94022
Phone+1 650-690-2362

Fax+1 650-590-4938
Is this information wrong?

Summary

Dr. Saad A. Shakir is an American Psychiatrist who is board certified by the American Board of Psychiatry & Neurology. He is the founder and former medical director of Silicon Valley TMS, a private practice group that provides a multidisciplinary team of clinicians to deliver individually tailored treatments for patients and their families. He is also the chief of innovative therapy, including TMS, at Refresh Mental Health Group. Dr. Shakir has been actively involved in the development and promotion of Transcranial Magnetic Stimulation (TMS), an FDA-approved treatment for depression that is non-invasive and without systemic side effects. He has been a founding board member of the Clinical TMS Society, a national and international TMS society, and has served as past president of the Northern California TMS Society. In addition to his clinical work, Dr. Shakir has been an Adjunct Clinical Associate Professor Emeritus at Stanford University School of Medicine, Department of Psychiatry and Behavioral Medicine, and has held various other leadership roles in the medical community. He is also a co-developer of the Care Program for Refugees (CPR), a nonprofit program that provides medical and psychiatric assessments and treatments to victims of trauma, war, and refugees in war-torn countries.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Psychiatry, 1976 - 1978
New York Presbyterian Hospital (Columbia Campus)/New York State Psychiatric InstituteResidency, Psychiatry, 1974 - 1976
University of Baghdad College of MedicineClass of 1972

Certifications & Licensure

CA State Medical License 1976 - 2025
ME State Medical License Active through 1980
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

An Observational Modified Prescription-event Monitoring Study of Asenapine (Sycrest) Start of enrollment: 2012 Jan 01
Completed

Publications & Presentations

PubMed

3 citations
Long-term outcomes of a course of deep TMS for treatment-resistant OCD.
Tal Harmelech, Aron Tendler, Mehmet Kemal Arikan, Hamide Laçin Çetin, Muhammed Taha Esmeray, Reyhan Ilhan, Ryan Vidrine, Owen Muir, Carlene MacMillan, Rebecca Sinclair...> ;Brain Stimulation. 2022 Jan 1
28 citations
Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites.
Yiftach Roth, Aron Tendler, Mehmet Kemal Arikan, Ryan Vidrine, David Kent, Owen Muir, Carlene MacMillan, Leah S. Casuto, Geoffrey Grammer, William Sauve, Kellie Tolin,...> ;Journal of Psychiatric Research. 2021 May 1
Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-Infective Agents: A Systematic Literature Review From the ARITMO Project.
Hazell L, Raschi E, De Ponti F, Thomas SHL, Salvo F, Ahlberg Helgee E, Boyer S, Sturkenboom M, Shakir S> ;J Clin Pharmacol. 2016-12-26
Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England.
McNaughton R, Lynn E, Osborne V, Coughtrie A, Layton D, Shakir S> ;Drug Saf. 2016-04-01
Development Of A Collaborative European Pharmacoepidemiologic Post-Authorization Safety Study (Pass) Programme Examining Rivaroxaban Use In Routine Clinical Practice.
Brobert G, García RLA, Garbe E, Bezemer ID, Layton D, Friberg L, Suzart-Woischnik K, Alderson J, Winchester C, Herings RMC, Jobski K, Schink T, Shakir S, Soriano-Gabar...> ;Value Health. 2014-11-01
An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
McNaughton R, Huet G, Shakir S> ;BMJ Open. 2014-01-15
Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescriptio...
Davies M, Wilton L, Shakir S> ;Drug Saf. 2013-04-01
How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
Hazell L, Cornelius V, Hannaford P, Shakir S, Avery AJ> ;Drug Saf. 2013-03-01
Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes.
Behr ER, Ritchie MD, Tanaka T, Kääb S, Crawford DC, Nicoletti P, Floratos A, Sinner MF, Kannankeril PJ, Wilde AAM, Bezzina CR, Schulze-Bahr E, Zumhagen S, Guicheney P,...> ;PLoS ONE. 2013-01-01
Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia.
Jamshidi Y, Nolte IM, Dalageorgou C, Zheng D, Johnson T, Bastiaenen R, Ruddy S, Talbott D, Norris KJ, Snieder H, George AL, Marshall V, Shakir S, Kannankeril PJ, Munro...> ;J. Am. Coll. Cardiol.. 2012-08-28
The safety of H1N1 vaccine in children in Saudi Arabia: a cohort study using modern technology in a developing country.
Aljadhey H, Alyabsi M, Alrwisan A, Alqahtani N, Almutairi R, Al Tawil E, Adam M, Shakir S, Aljeraisy M, Al-Blowi A, Alkhashan H, Albogami Y, Murray MD> ;Drug Saf. 2012-07-01
Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes.
Mackenzie IS, MacDonald TM, Shakir S, Dryburgh M, Mantay BJ, McDonnell P, Layton D> ;Br J Clin Pharmacol. 2012-05-01
A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes.
Kääb, S., Crawford, D. C., Sinner, M. F., Behr, E. R., Kannankeril, P. J., Wilde, A. A., Bezzina, C. R., Schulze-Bahr, E., Guicheney, P., Bishopric, N. H., Myerburg, R...> ;Circ Cardiovasc Genet. 2012 Feb 1
Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data.
Layton, D., Osborne, V., Gilchrist, A., Shakir, S. A.> ;Drug Saf. 2011 Dec 1
Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management.
Layton, D., Hazell, L., Shakir, S. A.> ;Drug Saf. 2011 Dec 1
Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England.
Buggy, Y., Cornelius, V., Wilton, L., Shakir, S. A.> ;Drug Saf. 2011 Jun 1
Paediatric post-marketing pharmacovigilance: comparison of the adverse event profile of vigabatrin prescribed to children and adults.
Aurich-Barrera, B., Wilton, L., Brown, D., Shakir, S.> ;Pharmacoepidemiol Drug Saf. 2011 Jun
Evaluation of patient reporting of adverse drug reactions to the UK ''Yellow Card Scheme'': literature review, descriptive and qualitative analyses, and questionnaire ...
Avery, A. J., Anderson, C., Bond, C. M., Fortnum, H., Gifford, A., Hannaford, P. C., Hazell, L., Krska, J., Lee, A. J., McLernon, D. J., Murphy, E., Shakir, S., Watson...> ;Health Technol Assess. 2011 May
New postgraduate qualifications in pharmacovigilance from the Drug Safety Research Unit in the UK.
Lynn, E., Layton, D., Shakir, S.> ;Drug Saf. 2011 Jan 1
Hypoglycaemia with pioglitazone: analysis of data from the Prescription-Event Monitoring study.
Vlckova, V., Cornelius, V., Kasliwal, R., Wilton, L., Shakir, S.> ;J Eval Clin Pract. 2010 Dec
Paediatric postmarketing pharmacovigilance using prescription-event monitoring: comparison of the adverse event profiles of lamotrigine prescribed to children and adul...
Aurich-Barrera, B., Wilton, L., Brown, D., Shakir, S.> ;Drug Saf. 2010 Sep 1
Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.
Osborne, V., Layton, D., Perrio, M., Wilton, L., Shakir, S. A.> ;Drug Saf. 2010 Jul 1
Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
Buggy, Y., Layton, D., Fogg, C., Shakir, S. A.> ;Epilepsia. 2010 May
Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk management.
Osborne, V., Hazell, L., Layton, D., Shakir, S. A.> ;Drug Saf. 2010 Mar 1
Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality.
Cornelius, V. R., Perrio, M. J., Shakir, S. A., Smith, L. A.> ;Pharmacoepidemiol Drug Saf. 2009 Dec 01
Join now to see all

Journal Articles

Challenges for Drug Repurposing in the COVID-19 Pandemic Era
Saad Shakir, MD, Frontiers in Pharmacology

Press Mentions

COVID-19 vs. COVID-19 Vaccine: Risk of Neurological ComplicationsNovember 1st, 2021
Meet the Speakers – FPM Annual SymposiumAugust 9th, 2021
Oxford/AstraZeneca Jab Could Have Causal Link to Rare Blood Clots, Say UK ExpertsApril 6th, 2021
Join now to see all